Inspiremd reports second quarter 2024 financial results and provides business update

- announced positive outcomes from the c-guardians ide clinical trial of the cguard™ prime carotid stent system demonstrating a one-year primary endpoint event rate of 1.95%, the lowest for any carotid stent or embolic protection device pivotal trial –
NSPR Ratings Summary
NSPR Quant Ranking